Position in ANL
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$14,192
New position
Shares Held
2,051
first reported quarter
Ownership
0.003%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026ANTIPODES PARTNERS Ltd holds $54,404,721 across 20 Biotechnology names. ANL ranks #20 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
145,310 | $48,078,719 | |
| 2 | HUMA |
Humacyte, Inc.
|
5,723,750 | $3,474,316 | |
| 3 | GPCR |
Structure Therapeutics Inc.
|
45,361 | $2,186,400 | |
| 4 | IMNM |
Immunome Inc.
|
7,818 | $170,979 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
97 | $74,946 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
127 | $56,710 | |
| 7 | TARS |
Tarsus Pharmaceuticals, Inc.
|
555 | $38,933 | |
| 8 | ARGX |
Argenx SE
|
50 | $36,512 |
All Filings in ANL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $14,192 | 2,051 | Shares | Sole | 2026-05-05 | |
| No filing history on record for this holder in this stock. | ||||||